Moleculin Biotech (NASDAQ:MBRX – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research report issued on Wednesday.
A number of other equities research analysts have also weighed in on the company. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Moleculin Biotech in a research note on Monday. Maxim Group raised shares of Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Tuesday.
Check Out Our Latest Stock Analysis on Moleculin Biotech
Moleculin Biotech Price Performance
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Read More
- Five stocks we like better than Moleculin Biotech
- Why is the Ex-Dividend Date Significant to Investors?
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Overbought Stocks Explained: Should You Trade Them?
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
